PMID- 17928430
OWN - NLM
STAT- MEDLINE
DCOM- 20080226
LR  - 20211020
IS  - 1556-679X (Electronic)
IS  - 1556-6811 (Print)
IS  - 1556-679X (Linking)
VI  - 14
IP  - 12
DP  - 2007 Dec
TI  - Use of an experimental model to test the efficacy of planned exposure to live 
      porcine reproductive and respiratory syndrome virus.
PG  - 1572-7
AB  - The objectives of this study were to test the efficacy and safety of planned 
      exposure to porcine reproductive and respiratory syndrome virus (PRRSV) in 
      protecting naive and previously exposed pigs against PRRSV challenge and to gain 
      information on the dose of PRRSV necessary to induce a protective immune 
      response. Fifty 2-week-old pigs were randomly assigned to one of five groups: a 
      group exposed to a low dose of autogenous PRRSV vaccine (the L-VAC group), a 
      group exposed to a high dose of autogenous vaccine (the H-VAC group), a group 
      exposed to a low dose of a heterologous PRRSV strain (strain SDSU73) prior to 
      planned exposure (the SDSU73-L-VAC group), a group exposed to a high dose of a 
      heterologous PRRSV strain (strain SDSU73) prior to planned exposure (the 
      SDSU73-H-VAC group), and a control group. All groups were challenged with PRRSV 
      VR2385 5 weeks after the planned exposure. Necropsy was done 2 weeks after the 
      PRRSV challenge. The H-VAC, SDSU73-L-VAC, and SDSU73-H-VAC groups had 
      significantly (P < 0.05) less severe clinical disease (sneezing, respiratory 
      scores, and weight gain), significantly (P < 0.05) less severe macroscopic and 
      microscopic lung lesions, and significantly (P < 0.05) lower numbers of PRRSV 
      genomic copy numbers in their sera compared to the results for the control group. 
      Planned exposure to live PRRSV can be used as an inexpensive and effective way to 
      decrease the severity of PRRSV-induced disease following subsequent challenge.
FAU - Opriessnig, Tanja
AU  - Opriessnig T
AD  - Department of Veterinary Diagnostic and Production Animal Medicine, College of 
      Veterinary Medicine, Iowa State University, Ames, IA 50011, USA. 
      tanjaopr@iastate.edu
FAU - Baker, Rodney B
AU  - Baker RB
FAU - Halbur, Patrick G
AU  - Halbur PG
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071010
PL  - United States
TA  - Clin Vaccine Immunol
JT  - Clinical and vaccine immunology : CVI
JID - 101252125
RN  - 0 (Antibodies, Viral)
RN  - 0 (RNA, Viral)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Administration, Intranasal
MH  - Animals
MH  - Antibodies, Viral/blood
MH  - Control Groups
MH  - Enzyme-Linked Immunosorbent Assay/veterinary
MH  - Gene Dosage
MH  - Neutralization Tests/veterinary
MH  - Porcine respiratory and reproductive syndrome 
      virus/genetics/*immunology/isolation & purification/pathogenicity
MH  - RNA, Viral/blood/isolation & purification
MH  - Random Allocation
MH  - Risk Factors
MH  - Serologic Tests/veterinary
MH  - Sus scrofa
MH  - Swine Diseases/blood/*immunology/pathology/*prevention & control/virology
MH  - Time Factors
MH  - Treatment Outcome
MH  - Viral Vaccines/administration & dosage/adverse effects/*immunology/*therapeutic 
      use
MH  - Viremia
PMC - PMC2168385
EDAT- 2007/10/12 09:00
MHDA- 2008/02/27 09:00
PMCR- 2008/04/01
CRDT- 2007/10/12 09:00
PHST- 2007/10/12 09:00 [pubmed]
PHST- 2008/02/27 09:00 [medline]
PHST- 2007/10/12 09:00 [entrez]
PHST- 2008/04/01 00:00 [pmc-release]
AID - CVI.00332-07 [pii]
AID - 0332-07 [pii]
AID - 10.1128/CVI.00332-07 [doi]
PST - ppublish
SO  - Clin Vaccine Immunol. 2007 Dec;14(12):1572-7. doi: 10.1128/CVI.00332-07. Epub 
      2007 Oct 10.